Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,518 questions in 135 reviews · Infectious Diseases
current versionsNo studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.65 [0.17, 2.5] | 1 study · 1007 participants | Low |
Intervention NR Severe adverse events: raised amylase · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 1.4 [0.72, 2.73] | 2 studies · 1071 participants | Low |
Intervention NR Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 1.1 [0.39, 3.13] | 2 studies · 1071 participants | Low |
Intervention NR Severe adverse events: neutropenia · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.48 [0.28, 0.82] | 3 studies · 1799 participants | High |
Intervention NR Severe adverse events: rash · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.58 [0.34, 1] | 7 studies · 2277 participants | Moderate |
Intervention NR Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT) · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | no estimate extracted | 1 study · 135 participants | Moderate |
Intervention NR Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | no estimate extracted | 1 study · 135 participants | Moderate |
Intervention NR Raised cholesterol · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 6.03 [0.75, 48.78] | 1 study · 64 participants | Moderate |
Intervention NR Mortality · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.84 [0.59, 1.19] | 8 studies · 2317 participants | Moderate |
Intervention NR Progression to AIDS · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 1.23 [0.72, 2.11] | 5 studies · 2005 participants | Moderate |
Intervention NR All severe adverse events · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.91 [0.71, 1.18] | 8 studies · 2329 participants | Very low |
Intervention NR Discontinuation rate · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.93 [0.69, 1.25] | 9 studies · 2384 participants | Moderate |
Intervention NR Change in CD4 count · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | no estimate extracted | 9 studies · 1829 participants | Moderate |
Intervention NR Treatment failure · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.97 [0.76, 1.24] | 5 studies · 737 participants | Low |
Intervention NR Severe adverse events: central nervous system · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 4.46 [1.65, 12.03] | 6 studies · 2049 participants | Moderate |
Intervention NR Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse… (2016) · Cochrane | RR 0.76 [0.48, 1.21] | 6 studies · 2049 participants | Low |
Intervention NR Duration of diarrhoea · children with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 9 studies · 2581 participants | Low |
Intervention NR Adverse events (vomiting) · children aged less than 6 months with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 1.54 [1.05, 2.24] | 2 studies · 1334 participants | Moderate |
Intervention NR Duration of diarrhoea · children with persistent diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 5 studies · 529 participants | Moderate |
Intervention NR Diarrhoea on day 7 · children with persistent diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 0.52 [0.27, 1.02] | 2 studies · 221 participants | Low |
Intervention NR Hospitalization · children with persistent diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 1 study · 275 participants | Very low |
Intervention NR Death · children with persistent diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 3 studies · 402 participants | Very low |
Intervention NR Adverse events (vomiting) · children with persistent diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 1.97 [0.37, 10.59] | 4 studies · 505 participants | Very low |
Intervention NR Diarrhoea on day 7 · children with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 0.73 [0.61, 0.88] | 6 studies · 3865 participants | Moderate |
Intervention NR Number of children hospitalized (community trials only) · children with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 1 study · 276 participants | Very low |
Intervention NR Death · children with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 0.29 [0.04, 2.2] | 4 studies · 1134 participants | Very low |
Intervention NR Adverse events (vomiting) · children with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 1.57 [1.32, 1.86] | 6 studies · 2605 participants | Moderate |
Intervention NR Duration of diarrhoea · children aged less than 6 months with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | MD 5.23 | 2 studies · 1334 participants | Low |
Intervention NR Diarrhoea on day 7 · children aged less than 6 months with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 1.24 [0.99, 1.54] | 1 study · 1074 participants | Low |
Intervention NR Number of children hospitalized (community trials only) · children aged less than 6 months with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | no estimate extracted | 1 study · 1074 participants | Very low |
Intervention NR Death · children aged less than 6 months with acute diarrhoea Oral zinc for treating diarrhoea in children (2016) · Cochrane | RR 1 [0.06, 15.89] | 2 studies · 1334 participants | Very low |
Intervention NR Death (at 6 months) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 0.34 [0.1, 1.2] | 4 studies · 567 participants | Very low |
Intervention NR Remaining sputum positive (at 4 weeks) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 0.92 [0.63, 1.35] | 2 studies · 1020 participants | Very low |
Intervention NR Weight gain · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 5 studies · 2940 participants | Low |
Intervention NR Quality of life · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Cured (at 6 months) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 0.91 [0.59, 1.41] | 1 study · 102 participants | Very low |
Intervention NR Treatment completion (at 6 months) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 2 studies · 365 participants | Very low |
Intervention NR Sputum negative (at 8 weeks) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 1.08 [0.86, 1.37] | 3 studies · 222 participants | Very low |
Intervention NR Mean weight gain (At 8 weeks) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 5 studies · 883 participants | Moderate |
Intervention NR Quality of life (At 8 weeks) · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 2 studies · 134 participants | Low |
Intervention NR Death · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 0.86 [0.46, 1.6] | 4 studies · 1219 participants | Low |
Intervention NR Cure rate · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Treatment completion · adults and children with active tuberculosis Nutritional supplements for people being treated for active tuberculosis (2016) · Cochrane | RR 0.99 [0.95, 1.04] | 1 study · 302 participants | Very low |
Educational interventions vs no intervention HIV prevalence · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 1.03 [0.8, 1.32] | 3 studies · 14163 participants | Low |
Combined incentive‐based and educational interventions vs no intervention HSV2 prevalence · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 0.82 [0.68, 0.99] | 1 study · 5899 participants | Low |
Combined incentive‐based and educational interventions vs no intervention Syphillis prevalence · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Combined incentive‐based and educational interventions vs no intervention Pregnant at end of trial · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 0.9 [0.67, 1.19] | 1 study · 2782 participants | Low |
Educational interventions vs no intervention HSV2 prevalence · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 1.04 [0.94, 1.15] | 3 studies · 17445 participants | Moderate |
Educational interventions vs no intervention Syphillis prevalence · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 0.81 [0.47, 1.39] | 1 study · 6977 participants | Low |
Educational interventions vs no intervention Pregnant at end of trial · adolescents School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents (2016) · Cochrane | RR 0.99 [0.85, 1.16] | 3 studies · 8280 participants | Moderate |